Evidence map›Paper›PMID 33947250›Full record

ReviewInterventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences2022

Glycoprotein IIb/IIIa inhibitors for the neurointerventionalist.

Davide Simonato, Robin J Borchert, Marc-Antoine Labeyrie, Maurizio Fuschi, Lucie Thibault, Hans Henkes, David Fiorella, Benjamin Yq Tan, Leonard Ll Yeo, Hegoda Ld Makalanda and 2 more

Abstract readReview
In one paragraph

Review in Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. P2Y12 inhibitors for the neurointerventionalist.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Davide SimonatoDepartment of Neuroradiology, Oxford University Hospital NHS Foundation Trust, UK.ORCID https://orcid.org/0000-0003-3601-9136
Robin J BorchertDepartment of Clinical Neurosciences, University of Cambridge, UK.
Marc-Antoine LabeyrieInterventional Neuroradiology Unit, Lariboisiere Hospital, France.
Maurizio FuschiDepartment of Neuroradiology, Oxford University Hospital NHS Foundation Trust, UK.
Lucie ThibaultWFITN Scientific Committee Member, Paris, France.
Hans HenkesClinic for Neuroradiology, Klinikum Stuttgart, Stuttgart, Germany.
David FiorellaDepartment of Neurosurgery, Stony Brook University Hospital, New York, USA.
Benjamin Yq TanDivision of Neurology, National University Health System and Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Leonard Ll YeoDivision of Neurology, National University Health System and Yong Loo Lin School of Medicine, National University of Singapore, Singapore.ORCID https://orcid.org/0000-0002-4249-0402
Hegoda Ld MakalandaRoyal London Hospital, London, UK.
Ken WongRoyal London Hospital, London, UK.
Pervinder BhogalRoyal London Hospital, London, UK.ORCID https://orcid.org/0000-0002-5514-5237

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antiplatelet therapies are commonly used in neurointerventional procedures. However, specific guidelines for their use in these settings is lacking and it can often be difficult to balance the potential risks and benefits of these medications. Considering the continued growth and adoption of neurointerventional procedures, it is crucial to understand the properties of these agents in order to use them safely. Large-scale clinical trials are still needed to clarify many of these aspects for this emerging field. However, the existing literature already provides insight into which antiplatelet drugs are of benefit to the neurointerventionalist as well as their associated risks of ischemic and hemorrhagic complications. Hence, this review focuses on the applications of GPIIb/IIIA inhibitors to neurointerventional procedures.

Indexed as

Platelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexHumansPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexaneurysmhemorrhagePlateletsstrokethrombectomy

Identifiers

PMID33947250
PMCPMC8905078

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.